Proteomic aging clock (PAC) predicts age-related outcomes in middle-aged and older adults

Chia-Ling Kuo,Zhiduo Chen,Peiran Liu,Luke C. Pilling,Janice L. Atkins,Richard H. Fortinsky,George A. Kuchel,Breno S. Diniz
DOI: https://doi.org/10.1101/2023.12.19.23300228
2024-04-21
Abstract:Beyond mere prognostication, optimal biomarkers of aging provide insights into qualitative and quantitative features of biological aging and might, therefore, offer useful information for the testing and, ultimately, clinical use of gerotherapeutics. We aimed to develop a proteomic aging clock (PAC) for all-cause mortality risk as a proxy of biological age. Data were from the UK Biobank Pharma Proteomics Project, including 53,021 participants aged between 39 and 70 years and 2,923 plasma proteins assessed using the Olink Explore 3072 assay®. The Spearman correlation between PAC proteomic age and chronological age was 0.77. A total of 10.9% of the participants died during a mean follow-up of 13.3 years, with the mean age at death 70.1 years. We developed a proteomic aging clock (PAC) for all-cause mortality risk as a surrogate of BA using a combination of least absolute shrinkage and selection operator (LASSO) penalized Cox regression and Gompertz proportional hazards models. PAC showed robust age-adjusted associations and predictions for all-cause mortality and the onset of various diseases in general and disease-free participants. The proteins associated with PAC were enriched in several processes related to the hallmarks of biological aging. Our results expand previous findings by showing that age acceleration, based on PAC, strongly predicts all-cause mortality and several incident disease outcomes. Particularly, it facilitates the evaluation of risk for multiple conditions in a disease-free population, thereby, contributing to the prevention of initial diseases, which vary among individuals and may subsequently lead to additional comorbidities.
Genetic and Genomic Medicine
What problem does this paper attempt to address?
The problem this paper attempts to address is the development of a Proteomic Aging Clock (PAC) to predict all-cause mortality risk in middle-aged and older adults, serving as a proxy indicator of biological age. Specifically, the researchers utilized data from the UK Biobank Pharma Proteomics Project, which includes 53,021 participants aged 39 to 70 and 2,923 plasma proteins. By combining Least Absolute Shrinkage and Selection Operator (LASSO) penalized Cox regression and Gompertz proportional hazards models, the researchers developed PAC and validated its predictive ability for all-cause mortality and other age-related diseases in both general and disease-free populations. Additionally, the study explored the enrichment of proteins associated with PAC in biological aging marker processes, aiming to provide tools for assessing the risk of various conditions, thereby aiding in the prevention of initial diseases and their potential subsequent complications. In short, the main goal of this study is to better understand the process of biological aging by developing a reliable proteomic aging clock and to provide a new tool for assessing individual health status and predicting potential health risks. This not only aids scientific research but may also support clinical applications in the future, such as testing and eventual clinical use of anti-aging therapies.